A novel coronavirus (COVID-19) has caused a global pandemic. There is currently no vaccine or antiviral treatment. The most serious complication from COVID-19 is death often from acute respiratory distress syndrome (ARDS) [@b0005].

Neutrophils are chemotaxic to many signaling gradients, interleukin-8 (IL-8) being one. ARDS patients have elevated IL-8 in bronchoalveolar lavage fluid and other neutrophil chemoattractants are present and act in synergy with that IL-8 [@b0010].

Evidence points to the ability of dapsone to inhibit neutrophil chemotaxis to both N-formylmethionyl-leucyl-phenylalanine and to IL-8 via interference with neutrophils' adherence functions [@b0015], [@b0020].

To work in concert and synergy with with Dapsone, we note that colchicine [@b0025]---a drug that has been used for millennia---is also a potent neutrophil inhibitor working by inhibiting microtuble polymerization.

One risk factor for mortality identified in patients hospitalized with COVID-19 infection is elevated Il-6 levels [@b0005]. Histamine acting through the H1 receptor is a strong positive regular of Il-6 [@b0030]. Atypical antipsychotic medications such as olanzapine and quetiapine are particular potent H1 antagonists [@b0035], [@b0040] and thus we think thus could be most useful in lowering Il-6 levels.

A trial of dapsone 100 mg every 12 h, colchicine 0.4 mg daily and olanzapine 10 mg daily in hospitalized but not yet ventilated patients may be warranted.
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